

# Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer (Review)

CAROLINE E. McCARTHY<sup>1,2</sup>, JOHN K. FIELD<sup>1,2</sup> and MICHAEL W. MARCUS<sup>1</sup>

<sup>1</sup>Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, The University of Liverpool Institute of Translational Medicine, Liverpool L7 8TX;

<sup>2</sup>Department of Oral Medicine, Liverpool University Dental Hospital, Liverpool L69 3BX, UK

Received September 2, 2016; Accepted February 16, 2017

DOI: 10.3892/or.2017.5867

**Abstract.** There were ~986,000 cases of head and neck cancer (HNC) and oesophageal cancer diagnosed worldwide in 2012. The incidence of these types of cancer is much higher in males than females, although this disparity decreases in the elderly population, suggesting a role for hormones as a risk factor. This systematic review investigates the potential role of female hormones [age at menopause and use of hormone replacement therapy (HRT)] as risk factors for HNC/oesophageal squamous cell carcinoma (SCC). The electronic databases MEDLINE, Web of Science, EMBASE and Cochrane were searched. Only studies with at least 50 cases of HNC/oesophageal SCC, with data on age at menopause, smoking, alcohol, age and socio-economic status or educational attainment, were included. The Newcastle Ottawa Scale was used for assessing risk of bias. Eight studies met the inclusion criteria (5 oesophageal SCC, 2 HNC and 1 combined oesophageal SCC and HNC). HRT was shown to reduce the risk of HNC (HR, 0.78; 95% CI, 0.61-0.99) in one study. Our results showed that earlier age at menopause is a risk factor for oesophageal SCC, with women entering menopause at <45 years having double the risk of those entering menopause at age >50 years. Similar, but less striking, results were observed for HNC. HRT was found to reduce the risk of HNC/oesophageal SCC, but the evidence is inconclusive. We, therefore, recommend that consideration should be given to collecting data on reproductive factors and exposure to HRT, as routine practice, in future epidemiological and clinical studies of these cancers. The concept of oestrogen deficiency as a risk for HNC/oesophageal SCC deserves further exploration in future laboratory and clinical studies.

## Contents

1. Introduction
2. Methods
3. Search results
4. Hormone replacement therapy (HRT)
4. Age at menopause
5. Discussion

## 1. Introduction

There were ~986,000 cases of head and neck cancer (HNC), and oesophageal cancer diagnosed worldwide in 2012. In the same year, in the UK, there were 5,000 cases of HNC in males and 2,500 in females (1). In 2013, there were 8,784 cases of oesophageal cancer, with a male:female ratio of 2:1. This makes HNC and oesophageal cancer the 12th and 13th most common cancers in the UK (2). The ratio of male:female cases of HNC in persons aged 50-60 years is ~3:1, however, the gender disparity is reduced in the elderly population, with a male:female ratio of 1.5:1 in individuals over 80 years of age (3). For oesophageal squamous cell carcinoma (SCC) the male:female ratio is lower, at 1.1:1.

Understanding the differences between subgroups of the population is important to ensure that policy makers can make informed decisions regarding preventive measures. Smoking and alcohol are the major risk factors for HNC and oesophageal SCC; however, the differences in incidence between age categories cannot be solely attributed to differences in smoking and alcohol consumption (4). Hormones are known to play an important role in several types of cancers, such as breast, ovarian and uterine, endometrial, prostate, testis and thyroid cancers.

Studies have been carried out on hormone-related risk factors for squamous cancers, such as oesophageal, cervical and lung cancer (5). While hormone replacement therapy (HRT) is a known risk factor for certain cancers (e.g. breast cancer), a recent meta-analysis found that the use of HRT is protective against oesophageal SCC (6). Early-menopause has also been linked to an increased risk of oesophageal SCC [risk ratio (RR), 1.32 (95% CI, 1.11-1.56)/5 years younger at menopause] (7). Another meta-analysis suggested decreased

---

*Correspondence to:* Dr Michael W. Marcus, Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, The University of Liverpool Institute of Translational Medicine, The William Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK  
E-mail: m.w.marcus@liverpool.ac.uk

**Key words:** age at menopause, hormone replacement therapy, risk factors, head and neck cancer, oesophageal cancer, systematic review

risk of lung cancer in never-smoker females who use HRT [OR, 0.86 (95% CI, 0.75-0.99)]. This leads to the hypothesis that hormone levels may be a potential risk factor for squamous cancers. There is uncertainty surrounding the role of female hormones and the risk of head and neck oesophageal SCC. However, to the best of our knowledge, no systematic review has been conducted to address this uncertainty. The aim of this systematic review was to address the uncertainty surrounding the role of female hormones and the risk of head and neck and oesophageal SCC by evaluating two specific questions: i) is early menopause a risk factor for HNC or oesophageal SCC and ii) is HRT protective against HNC or oesophageal SCC?

## 2. Methods

In the present study, we combined head and neck, and oesophageal SCC due to their histology and strong similarities in their epidemiology and aetiology.

**Search strategy.** Electronic databases MEDLINE, Web of Science, EMBASE and Cochrane were searched up until February 11, 2016. Search strategies were developed using Medical Subject Heading (MeSH) words such as: head and neck neoplasms, head and neck and oesophageal cancer, esophageal neoplasms, HRT, female hormone, early menopause and text words related to hormones and HNC or (o)esophageal cancer. Only search terms describing the association were used. Reference lists were also extensively searched and relevant papers obtained.

**Eligibility criteria.** Randomized controlled trials (RCTs), controlled (non-randomised) clinical trials (CCTs) or cluster trials, prospective and retrospective comparative cohort studies, case-control or nested case-control studies, and cross-sectional studies, addressing the question of female hormones as a risk factor for HNC or oesophageal SCC, were considered. Studies were included when they: i) examined the general adult population (age >18 years), specifically patients with at least 50 cases of HNC/oesophageal SCC and healthy controls; ii) addressed the question of HRT or reproductive factors (menopause) and HNC/oesophageal SCC; iii) administered HRT as an intervention for prevention of cancer or being therapeutically taken due to symptoms of menopause; iv) collected data on age at menopause, smoking, alcohol, age and socioeconomic status or educational attainment; and v) reported odds ratios, risk ratios or incidence/prevalence of HNC or oesophageal SCC defined using the World Health Organisation (WHO) classification of diseases ICD-10 codes, C00-15 and C30-31.

Cohort studies were only eligible when follow-up time was at least 5 years; case series and case reports were excluded. Only English language articles published in peer-reviewed journals, from 1948 to 2016, were considered.

**Data extraction.** Titles and/or abstracts of studies retrieved using the search strategy and those from additional sources were independently screened by two review authors (C.M. and M.M.), to identify studies that potentially met the inclusion criteria outlined above. Studies combining HNC with

oesophageal squamous cell cancers were considered, but data were extracted to separate HNC and oesophageal cancer where possible. Data were extracted in all forms (e.g. dichotomous, continuous) as reported in the included studies. The full texts of these potentially eligible studies were independently assessed for eligibility by C.M. and M.M. Any disagreement over the eligibility of particular studies was resolved through discussion with a third reviewer (J.K.F.).

**Risk of bias.** The risk of bias was assessed using the Newcastle Ottawa Scale which includes the following areas of evaluation of the risk of bias: selection of patients, comparability of groups in the study, methods for assessing outcomes, proof of exposure and appropriate follow-up. Studies were categorised as low, medium, high or unclear risk of bias, using a star-based scoring system. A maximum of 9 stars are available; the higher the number of stars the lower the risk of bias. For ease of interpretation, a score of 7 or greater is considered ‘low-risk’ of bias, 4-6 is ‘medium-risk’ and 3 or below is considered ‘high-risk’ of bias.

## 3. Search results

The search identified 13 potentially eligible studies following the review of titles and abstracts of studies identified from the initial search. One study considered HNC and oesophageal cancer separately, therefore was included in both arms of the review. Five papers were excluded, based on insufficient number of cases (n=2), failure to report an effect estimate/confidence intervals (n=2) and lack of categorisation by histopathological subtype (n=1). Eight studies met the inclusion criteria (4,7-13). The literature search results and selection process are depicted in Fig. 1A and B.

The systematic review includes two cohort studies (one oesophageal/HNC and one oesophageal cancer only) (7,8) with follow-up time of 7.5 and 9.1 years, respectively. Six case-control studies (4 oesophageal cancer and 2 HNC) (4,9-13) were also included. Studies covered the UK (7,13), USA (4,8), European continent (9,14) and China (11,12). The mean number of cases/study for the HNC articles was 214 (range 149-297). For oesophageal cancer, the average case number/study was 163 (range 56-578). A summary of the demographic data for each study is presented in Table I. A summary of the findings regarding use of HRT and risk of HNC/oesophageal SCC is shown in Table II A. Table II B summarises the findings regarding age at menopause.

## 4. Hormone replacement therapy (HRT)

**HNC.** Three papers (1 cohort study and 2 case-control studies) addressed the question of the use of HRT and incidence of HNC. Only the study by Freedman *et al* (8) was considered at ‘low-risk’ of bias, with a Newcastle Ottawa score of 7/9 stars. This was a cohort study conducted in the USA, using the NIH-AARP Diet and Health Cohort, of 125,887 women. Two hundred and ninety-seven cases of HNC were identified with mean follow-up of 7.5 years. The risk of HNC was 22% lower for ever-users of HRT (HR, 0.78; 95% CI, 0.61-0.99); 44.1% of cases (n=127) had ever-used HRT compared to 54.6% of controls (n=106,934). Further analysis by hysterectomy status




Figure 1. (A) Flow diagram of literature search results and selection process for head and neck cancer. (B) Flow diagram of literature search results and selection process for oesophageal cancer.

revealed that the risk reduction was greatest for women with an intact uterus who were current users of HRT for >5 years (HR, 0.23; 95% CI, 0.09-0.57). Notably, use of HRT other than oestrogen-alone or oestrogen-progesterone therapy conferred a greater risk of HNC (HR, 2.31; 95% CI, 1.15-4.65); however, this analysis was based on only 9 cases who used an alternative HRT. Two case-control studies were considered at medium/high risk of bias; they reported a non-significant reduction in the risk of HNC for ever-users of HRT (4,9).

**Oesophageal SCC.** Four studies analysed HRT use and the risk of oesophageal SCC. Two were considered low-risk of bias (8,13) and two were medium/high risk of bias (10,11). Although, all studies reported an effect estimate of <1 for

users of HRT, implying a protective effect, none of the results were statistically significant.

##### 5. Age at menopause

**HNC.** Two studies (8,9) assessed the link between age at menopause and risk of HNC. Bosetti *et al* (9) found a protective effect of later age at menopause (>50 years), with an OR of 0.46 (95% CI, 0.30-0.70). Freedman *et al* (8) found no significant effect on the risk of HNC with later age at menopause (>55 years).

**Oesophageal SCC.** Four out of 5 studies reported a significant effect of age at menopause and risk of oesophageal SCC. The

Table I. Demographic characteristics of the included studies.

First author (year) (ref.)	Country	Study type	Cancer type	Participant demographics	Time period
Freedman (2010) (8)	USA	Cohort	HNC/ oesophageal	NIH-AARP Diet and Health Study cohort, aged 50-71 years (median follow-up 7.5 years)	1995-2003
Langevin (2011) (4)	USA	Case-control	HNC	Cases of primary HNC and complaint-free hospital controls at ENT Department, University of Pittsburgh Medical Center	2006-2010
Bosetti (2000) (9)	Italy/ Switzerland	Case-control	HNC	Cases of histologically confirmed oral/ pharyngeal cancer age <75 years attending hospitals in Italy/Switzerland and hospital controls with acute, non-neoplastic conditions	1984-1997
Lindblad (2006) (13)	UK	Nested case-control	Oesophageal	UK General Practice Research Database (UK GPRD) cohort aged 50-84 years	1994-2001
Gallus (2003) (14)	Italy/ Switzerland	Case-control	Oesophageal	Cases aged <79 years with histologically confirmed oesophageal SCC admitted to study hospitals; hospital controls admitted to the same hospitals for acute, non-neoplastic conditions	1984-1999
Yu (2011) (11)	China	Case-control	Oesophageal	Cases of histopathologically confirmed oesophageal SCC; hospital based controls confirmed not to have oesophageal cancer	2008-2010
Chen (2011) (12)	China	Case-control	Oesophageal	Cases of newly diagnosed primary oesophageal cancer; hospital controls with no history of cancer	2004-2010
Green (2012) (7)	UK	Cohort	Oesophageal	Million Women Study cohort (women aged 50-64 years) with mean 9.1 years follow-up	1996-2008

HNC, head and neck cancer.

method of reporting varied. Gallus *et al* (10) reported an OR of 0.43 (95% CI, 0.22-0.83) for age at menopause of >50 years vs. menopause at age <45 years. Yu *et al* (11) reported an increased risk of oesophageal SCC for women entering menopause at <45 years (OR, 2.27; 95% CI, 1.03-4.97) and for 45-49 years (OR, 2.16; 95% CI, 1.14-4.78) compared to menopause at age >50 years. Green *et al* (7) reported increased risk of oesophageal SCC for every 5 years younger a woman was at the time of menopause (RR, 1.32; 95% CI, 1.11-1.56). Although, Freedman *et al* (8) found no significant effect for individual age categories, they did observe a significant trend ( $p=0.019$ ) for a lower risk of oesophageal SCC with older age at menopause. Chen *et al* (12) observed no significant effect for age at menopause, although these authors classified older age at menopause as >48 years.

## 6. Discussion

This systematic review has considered evidence from 8 studies investigating the risk of head and neck cancer (HNC) or oesophageal squamous cell carcinoma (SCC) in

relation to age at menopause and use of hormone replacement therapy (HRT); 5 studies investigated oesophageal SCC, 2 studies investigated HNC and 1 study included both cancers.

**Early menopause.** We found that earlier age at menopause is associated with a higher risk of oesophageal cancer, based on 4 studies with a total of 836 cases of oesophageal SCC.

Most women experience menopause between the ages of 45 and 55 years; the median age at menopause is 47.2 years, according to a prospective cohort study of over 5,000 women enrolled at the Royal College of GP's Oral Contraception study (15). Menopause is considered to be early in women aged 40-45 years (~5% of women) and premature in women <40 years (~1% of women) (16).

Early menopause is more frequent in women with certain genetic or autoimmune disorders, infections or a history of chemotherapy/radiotherapy or surgery to remove the ovaries (16).

Mean age of menopause for smokers is significantly lower than non-smokers (45.6 vs. 46.9 years) (15). Women with early natural menopause are more likely to be smokers, ever-users

Table II. The use of hormone replacement therapy and risk of HNC/oesophageal SCC, and age at menopause and risk of HNC/oesophageal SCC.

A, The use of hormone replacement therapy and risk of HNC/oesophageal SCC

Outcome of interest	First author (year) (ref.)	Type of study	No. of cases	Relative effect (OR or HR)	95% CI	Risk of Bias (Newcastle Ottawa Scale)
HNC	Freedman (2010) (8)	Cohort	297	<b>HR 0.78</b>	0.61-0.99	Low (8/9)
HNC	Langevin (2011) (4)	Case-control	149	OR 0.47	0.20-1.08	Medium (6/9)
HNC	Bosetti (2000) (9)	Case-control	195	OR 0.88	0.45-1.72	Medium-high (4/9)
Oesophageal SCC	Lindblad (2006) (13)	Nested case-control	74	OR 0.93	0.40-2.16	Low (9/9)
Oesophageal SCC	Gallus (2001) (10)	Case-control	114	OR 0.32	0.09-1.13	Medium-high (4/9)
Oesophageal SCC	Freedman (2010) (8)	Cohort	56	HR 0.74	0.42-1.26	Low (8/9)
Oesophageal SCC	Yu (2011) (11)	Case-control	88	OR 0.94	0.53-1.70	Medium-high (4/9)

Bold text denotes a statistically significant result.

B, Age at menopause and risk of HNC/oesophageal SCC

Outcome of interest	First author (year) (ref.)	Type of study	No. of cases	Age (years)	Relative effect (OR or HR)	95% CI	Risk of Bias (Newcastle Ottawa Scale)
HNC	Freedman (2010) (8)	Cohort	297	>55	HR 0.92	0.50-1.71	Low (8/9)
HNC	Bosetti (2000) (9)	Case-control	195	>50	<b>OR 0.46</b>	<b>0.30-0.70</b>	Medium-high (4/9)
Oesophageal SCC	Gallus (2001) (10)	Case-control	114	>50	<b>OR 0.43</b>	<b>0.22-0.83</b>	Medium-high (4/9)
Oesophageal SCC	Freedman (2010) (8)	Cohort	56	Increasing age	<b>Ptrend=0.019</b>		Low (8/9)
Oesophageal SCC	Yu (2011) (11)	Case-control	88	<45	<b>OR 2.27</b>	<b>1.03-4.97</b>	Medium-high (4/9)
Oesophageal SCC	Green (2012) (7)	Cohort	578	Per 5 years younger	<b>RR 1.32</b>	<b>1.11-1.56</b>	Low (7/9)
Oesophageal SCC	Chen (2011) (12)	Case-control	68	>48	OR 0.94	0.31-2.85	Medium (5/10)

HNC, head and neck cancer; SCC, squamous cell carcinoma; OR, odds ratio; HR, hazard ratio; CI, confidence interval; RR, risk ratio. Bold text denotes a statistically significant result.

of oral contraceptive medication, undergone tubal ligation, have at least one episode of endometriosis and are less likely to use HRT. No association with alcohol, BMI, physical activity or parity was reported (15). Diabetic women have also been found to be at risk of early menopause (OR, 2.76; 95% CI, 1.32-5.66) (17). In a pooled analysis of case-control studies, diabetes diagnosed at age <50 years conferred a greater risk of HNC (OR, 1.37; 95% CI, 1.07-1.74) when analysing 6,448 cases of HNC and 13,747 controls (18), but no link with age at menopause was considered in the present study.

A recent systematic review and meta-analysis of oesophageal SCC and reproductive factors also found a protective effect for older age at menopause (SRR=0.70; 95% CI, 0.51-0.95). The authors concluded that ‘properly extending the time of menstruation for pre-menopausal women is a possible way to reduce the risk of oesophageal SCC’ (19). A separate meta-analysis found that menopausal status was associated with higher risk of oesophageal SCC (RR, 1.66; 95% CI, 1.12-2.48), but age at menopause was not significant for Caucasians. In Asians, older age at menopause was found to confer greater risk

of oesophageal SCC (RR, 1.68; 95% CI, 1.05-2.70) (6). This implies that ethnicity and genetic background may influence the role of female hormones in oesophageal carcinogenesis.

The effect of age at menopause has been explored in several other cancer types. A meta-analysis of 8 studies of gastric cancer and reproductive factors found a protective effect of longer years of fertility (RR=0.74; 95% CI, 0.63-0.86) (20). Early menopause has also been found to be a risk factor for bladder cancer (meta-analysis including 7 studies: RR=1.59; 95% CI, 1.31-1.92) (21). Two studies from Hungary, from the same unit, found that the mean age at menopause was significantly lower in females with oral cancer compared to controls (43.5 vs. 50.9 and 45.4 years vs. 51.3 years, respectively) (22,23). These studies were excluded from this review due to the failure to provide accurate effect estimates with confidence intervals. Other recent meta-analyses found no significant effect of age at menopause in relation to risk of brain tumours (24), pancreatic (25) or thyroid cancer (26). A large cohort study found no association with age at menopause and risk of colorectal cancer (27).

HRT. HRT is long-established in the management of the symptoms of the menopause and has also been shown to reduce the risk of osteoporotic fractures, cardiovascular disease, Alzheimers, depression, stroke and colon cancer. Approximately 30% of UK women used HRT in 2001-2002 (28). Following this, a large US-based trial (Women's Health Initiative) was prematurely halted due to concerns over the evidence of increased risk of breast cancer, coronary heart disease, stroke and pulmonary embolism among users of HRT (29). The UK-based Million Women Study (MWS) also reported increased risk of breast cancer with HRT in 2003 (30). Following media coverage of the results of these trials, use of HRT declined steadily in the UK for the next 3-4 years. In 2005, only 10-11% of menopausal women were using HRT (28). Further reports of a slight increased risk of ovarian cancer for ever-users of HRT compounds enhanced concerns over the safety of HRT (31).

However, concerns have been raised by some authors surrounding the reporting of the WHI and MWS trial results, and the fact that little coverage was given to the evidence of the reduced incidence of osteoporotic fractures and colon cancer (32). Both trials recruited women aged over 50 years; therefore, the results cannot be applied to women who undergo premature menopause (33). HRT for women with premature menopause (primary ovarian insufficiency), prescribed up to the age of natural menopause (~51 years), is endorsed by the British Menopause Society and NICE guidelines. The NICE guidelines also recommend the development of a collaborative 'primary ovarian insufficiency' registry to allow data collection to clarify, among other factors, the long-term risk of cancers in this group (34).

Despite reports of an increased risk of breast and ovarian cancers in certain groups using HRT, there are many observational studies reporting a reduced risk of other cancers in HRT users. There are several reports of a reduced risk of colon cancer with HRT (27,35,36). Green *et al* reported a relative risk reduction of 17% (RR, 0.83; 95% CI, 0.79-0.88) in their meta-analysis of 30 studies of colorectal cancer and HRT (36). In a recent meta-analysis of oesophageal cancer and reproductive factors, the authors reported a 33% relative risk reduction with HRT use (SRR, 0.67; 95% CI, 0.56-0.81) (19). Similar results were reported for reduced risk of gastric cancers (RR, 0.77; 95% CI, 0.64-0.92) (20). Combined HRT (oestrogen and progesterone) has also been shown to reduce the risk of lung cancer, in a meta-analysis of 25 studies (RR, 0.83; 95% CI, 0.76-0.91) (37). HRT has not been found to significantly reduce the risk of melanoma or pancreatic cancer (25,38).

This systematic review did not find evidence of a significant risk reduction for oesophageal cancer among users of HRT, in contrast to the findings of the meta-analysis by Zhu *et al* (19). However, all effect estimates were <1 and the studies included contained only modest numbers of oesophageal cancer cases. The Freedman *et al* (8) cohort study included 297 cases of HNC and was the only study to report a significant relative risk reduction for HNC in users of HRT (HR, 0.78; 95% CI, 0.61-0.99). Further large studies are needed to confirm the finding that HRT is protective against HNC.

Confounding factors must be considered. Users of HRT tend to be of higher socioeconomic status (SES) and have higher levels of education. Both of these factors may reduce

the risk of HNC. To address this, only studies controlling for a measure of SES or education were eligible for inclusion in this review. Freedman *et al* (8) controlled for education, alcohol, BMI, tobacco smoking, physical activity and diet (fruit and vegetable intake), although residual confounding factors could still be relevant.

**Role of oestrogen deficiency.** Females have been found to have survival advantage for HNC, oesophageal, gastric and pancreatic cancer, as well as cancers at 11 other sites. For all cancers combined, women have a 5% lower risk of death than men; for HNC, a 12% increased survival is reported (39). This finding is consistent across all European regions in the EUROCARE-4 cohort of 1.6 million population-based cancer cases (39). The advantage is most pronounced in younger women and declines with age, with a marked decline beyond the age of menopause. It is possible that female hormones play a part in this 12% improvement in survival.

Oestrogen is known to promote cancer in oestrogen-responsive tissues, such as breast, endometrium and cervix; however, evidence from mouse models suggests that oestrogen has an inhibitory role in oesophageal SCC growth (40). Oestrogen receptors have been found in oesophageal SCC tissue samples and HNCs (40-42). Oesophageal SCC cells with oestrogen receptors have been shown to be inhibited by oestrogen exposure and this may initiate apoptosis (43). If oestrogen is responsible for inhibiting the growth of some cancer cells, oestrogen deficiency could be considered a risk factor for certain cancers. A woman who undergoes premature menopause has less oestrogen exposure over her lifetime and this may increase her risk of cancers such as oesophageal SCC. However, oestrogen appears to have both tumorigenic and antitumour properties, depending on the tissue and presence of oestrogen receptors. HNC cell lines, from males and females, have been found to contain oestrogen receptors, and laboratory studies appear to show that oestrogen promotes the growth of HNC cells (44,45). Further high quality basic science studies are required to confirm the role of oestrogen in HNC and oesophageal SCC.

The studies included in this review were all assessed for risk of bias, using the Newcastle Ottawa Scale. Only 3 of the 8 studies included were low risk for bias. This does limit the significance of our findings and is an indication of the need for further, high quality, studies addressing the issue of female hormones and squamous cancers.

We only included studies that controlled for significant potential confounding factors, such as smoking and socio-economic status, however, the risk of residual confounding factors remains. Smokers undergo menopause at a younger age than non-smokers. We recommend that future studies should control for this important confounder.

The rationale for combining HNC and oesophageal SCC is based on the strong similarities in their epidemiology and aetiology as mentioned earlier. We deliberately excluded oesophageal adenocarcinomas as these cancers have quite different aetiology. One of the studies included in our review by Bosetti *et al* (9) failed to clarify the histology of the oral/pharyngeal cancer cases included, which introduces a potential source of bias. However, over 90% of oral cancers and >80% of pharyngeal cancers are of squamous histology (46), therefore the bias is unlikely to be significant.

We found that earlier age at menopause is a risk factor for oesophageal SCC, with women entering menopause at <45 years having double the risk of those entering menopause at age >50 years. Similar, but less striking, results were observed for HNC. HRT was found to reduce the risk of HNC/oesophageal SCC, but the evidence is inconclusive. We used strict eligibility criteria and only considered studies that controlled for other risk factors, however, there is still the risk of residual bias. Consideration should be given to collecting data on reproductive factors and exposure to HRT, as routine practice, in future epidemiological and clinical studies of these cancers. The concept of oestrogen deficiency as a risk for HNC/oesophageal SCC warrants further investigation in future laboratory and clinical studies.

### Acknowledgements

Mrs. Caroline McCarthy is funded by NIHR (Academic Clinical Fellowship in Oral Medicine). The present review presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

### References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: E359-E386, 2015.
2. McCarthy CE, Field JK, Rajlawa BP, Field AE and Marcus MW: Trends and regional variation in the incidence of head and neck cancers in England: 2002 to 2011. *Int J Oncol* 47: 204-210, 2015.
3. Statistics OfN. Cancer Registration Statistics, England, 2013. 2015.
4. Langevin SM, Grandis JR and Taioli E: Female hormonal and reproductive factors and head and neck squamous cell carcinoma risk. *Cancer Lett* 310: 216-221, 2011.
5. Bae JM: Modifiable risk factors of lung cancer in 'never-smoker' women. *Epidemiol Health* 37: e2015047, 2015.
6. Wang BJ, Zhang B, Yan SS, Li ZC, Jiang T, Hua CJ, Lu L, Liu XZ, Zhang DH1, Zhang RS, et al: Hormonal and reproductive factors and risk of esophageal cancer in women: A meta-analysis. *Dis Esophagus* 29: 448-454, 2016.
7. Green J, Roddam A, Pirie K, Kirichek O, Reeves G and Beral V; Million Women Study collaborators: Reproductive factors and risk of oesophageal and gastric cancer in the Million Women Study cohort. *Br J Cancer* 106: 210-216, 2012.
8. Freedman ND, Lacey JV Jr, Hollenbeck AR, Leitzmann MF, Schatzkin A and Abnet CC: The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. *Cancer* 116: 1572-1581, 2010.
9. Bosetti C, Negri E, Franceschi S, Conti E, Levi F, Tomei F and La Vecchia C: Risk factors for oral and pharyngeal cancer in women: A study from Italy and Switzerland. *Br J Cancer* 82: 204-207, 2000.
10. Gallus S, Bosetti C, Franceschi S, Levi F, Simonato L, Negri E and La Vecchia C: Oesophageal cancer in women: Tobacco, alcohol, nutritional and hormonal factors. *Br J Cancer* 85: 341-345, 2001.
11. Yu H, Liu G, Zhao P and Zhu L: Hormonal and reproductive factors and risk of esophageal cancer in Chinese postmenopausal women: A case-control study. *Asian Pac J Cancer Prev* 12: 1953-1956, 2011.
12. Chen ZH, Shao JL, Lin JR, Zhang X and Chen Q: Reproductive factors and oesophageal cancer in Chinese women: A case-control study. *BMC Gastroenterol* 11: 49, 2011.
13. Lindblad M, García Rodríguez LA, Chandanos E and Lagergren J: Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. *Br J Cancer* 94: 136-141, 2006.
14. Gallus S, Bosetti C, Franceschi S, Levi F, Negri E and La Vecchia C: Laryngeal cancer in women: Tobacco, alcohol, nutritional, and hormonal factors. *Cancer Epidemiol Biomarkers Prev* 12: 514-517, 2003.
15. Pokoradi AJ, Iversen L and Hannaford PC: Factors associated with age of onset and type of menopause in a cohort of UK women. *Am J Obstet Gynecol* 205: 34.e1-34.e13, 2011.
16. Faubion SS, Kuhle CL, Shuster LT and Rocca WA: Long-term health consequences of premature or early menopause and considerations for management. *Climacteric* 18: 483-491, 2015.
17. Monterrosa-Castro A, Blümel JE, Portela-Buelvas K, Mezones-Holgún E, Barón G, Bencosme A, Benítez Z, Bravo LM, Calle A, Chedraui P, et al; Collaborative Group for Research of the Climacteric in Latin America (REDLINC): Type II diabetes mellitus and menopause: A multinational study. *Climacteric* 16: 663-672, 2013.
18. Stott-Miller M, Chen C, Chuang SC, Lee YC, Boccia S, Brenner H, Cadoni G, Dal Maso L, La Vecchia C, Lazarus P, et al: History of diabetes and risk of head and neck cancer: A pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidemiol Biomarkers Prev* 21: 294-304, 2012.
19. Zhu Y, Yue D, Yuan B, Zhu L and Lu M: Reproductive factors are associated with oesophageal cancer risk: Results from a meta-analysis of observational studies. *Eur J Cancer Prev* 26: 1-9, 2017.
20. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P and Rabkin CS: Sex hormones, hormonal interventions, and gastric cancer risk: A meta-analysis. *Cancer Epidemiol Biomarkers Prev* 21: 20-38, 2012.
21. Dietrich K, Demidenko E, Schned A, Zens MS, Heaney J and Karagas MR: Parity, early menopause and the incidence of bladder cancer in women: A case-control study and meta-analysis. *Eur J Cancer* 47: 592-599, 2011.
22. Suba Z: Gender-related hormonal risk factors for oral cancer. *Pathol Oncol Res* 13: 195-202, 2007.
23. Takács D, Koppány F, Mihályi S and Suba Z: Decreased oral cancer risk by moderate alcohol consumption in non-smoker postmenopausal women. *Oral Oncol* 47: 537-540, 2011.
24. Zong H, Xu H, Geng Z, Ma C, Ming X, Shang M, Li K, He X, Du H, Zhao J, et al: Reproductive factors in relation to risk of brain tumors in women: An updated meta-analysis of 27 independent studies. *Tumour Biol* 35: 11579-11586, 2014.
25. Tang B, Lv J, Li Y, Yuan S, Wang Z and He S: Relationship between female hormonal and menstrual factors and pancreatic cancer: A meta-analysis of observational studies. *Medicine* 94: e177, 2015.
26. Caini S, Gibelli B, Palli D, Saieva C, Ruscica M and Gandini S: Menstrual and reproductive history and use of exogenous sex hormones and risk of thyroid cancer among women: A meta-analysis of prospective studies. *Cancer Causes Control* 26: 511-518, 2015.
27. Arem H, Park Y, Felix AS, Zervoudakis A, Brinton LA, Matthews CE and Gunter MJ: Reproductive and hormonal factors and mortality among women with colorectal cancer in the NIH-AARP Diet and Health Study. *Br J Cancer* 113: 562-568, 2015.
28. Menon U, Burnell M, Sharma A, Gentry-Maharaj A, Fraser L, Ryan A, Parmar M, Hunter M and Jacobs I; UKCTOCS Group: Decline in use of hormone therapy among postmenopausal women in the United Kingdom. *Menopause* 14: 462-467, 2007.
29. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al; Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 288: 321-333, 2002.
30. Beral V, Banks E, Reeves G and Bull D; Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 362: 419-427, 2003.
31. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G and Peto R; Collaborative Group On Epidemiological Studies Of Ovarian Cancer: Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. *Lancet* 385: 1835-1842, 2015.
32. Studd J: 'PROFOX' - the post HRT nightmare. *Climacteric* 14: 217-219, 2011.
33. Ayres J: Premature menopause: Management challenges after the Women's Health Initiative. *J Br Menopause Soc* 11: 157, 2005.

34. (NICE) NIIfHaCE. Menopause: Diagnosis and management (NG23) 2015. NICE guideline. Published, 12 November 2015. nice.org.uk/guidance/ng23.
35. Murphy N, Strickler HD, Stanczyk FZ, Xue X, Wassertheil-Smoller S, Rohan TE, Ho GY, Anderson GL, Potter JD and Gunter MJ: A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. *J Natl Cancer Inst* 107: djv210, 2015.
36. Green J, Czanner G, Reeves G, Watson J, Wise L, Roddam A and Beral V: Menopausal hormone therapy and risk of gastrointestinal cancer: Nested case-control study within a prospective cohort, and meta-analysis. *Int J Cancer* 130: 2387-2396, 2012.
37. Yao Y, Gu X, Zhu J, Yuan D and Song Y: Hormone replacement therapy in females can decrease the risk of lung cancer: A meta-analysis. *PLoS One* 8: e71236, 2013.
38. Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F and Caini S: Hormonal and reproductive factors in relation to melanoma in women: Current review and meta-analysis. *Eur J Cancer* 47: 2607-2617, 2011.
39. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, Zambon P, Gatta G and De Angelis R; EUROCARE Working Group: The advantage of women in cancer survival: An analysis of EUROCARE-4 data. *Eur J Cancer* 45: 1017-1027, 2009.
40. Utsumi Y, Nakamura T, Nagasue N, Kubota H and Morikawa S: Role of estrogen receptors in the growth of human esophageal carcinoma. *Cancer* 64: 88-93, 1989.
41. Kalayarasan R, Ananthakrishnan N, Kate V and Basu D: Estrogen and progesterone receptors in esophageal carcinoma. *Dis Esophagus* 21: 298-303, 2008.
42. Lukits J, Remenár E, Rásó E, Ladányi A, Kásler M and Tímár J: Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer. *Int J Oncol* 30: 155-160, 2007.
43. Chandanos E and Lagergren J: The mystery of male dominance in oesophageal cancer and the potential protective role of oestrogen. *Eur J Cancer* 45: 3149-3155, 2009.
44. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR and Stabile LP: Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. *Clin Cancer Res* 15: 6529-6540, 2009.
45. Chang YL, Hsu YK, Wu TF, Huang CM, Liou LY, Chiu YW, Hsiao YH, Luo FJ and Yuan TC: Regulation of estrogen receptor  $\alpha$  function in oral squamous cell carcinoma cells by FAK signaling. *Endocr Relat Cancer* 21: 555-565, 2014.
46. Davies L and Welch HG: Epidemiology of head and neck cancer in the United States. *Otolaryngol Head Neck Surg* 135: 451-457, 2006.